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Conclusion: HNF4A gene encodes hepatocyte nuclear 
factor-4-alpha that regulates hepatic gluconeogenesis 
and lipid metabolism. Dominant inactivating variants 
in HNF4A gene associated with familial HI, are typi-
cally associated with increased size for gestational age, 
mild diazoxide-responsive hypoglycemia (which may be 
transient) and monogenic diabetes during adolescence. 
HNF4A mutations were described as one of the most 
common genetic cause of diazoxide-responsive congenital 
hyperinsulinism and are associated with MODY1. It is im-
portant to consider genetic evaluation in diazoxide respon-
sive HI cases. Identifying children with HNF4A variant 
early on will impact their long-term follow-up leading to 
earlier diagnosis and treatment of MODY-1 and potentially 
improve long-term outcomes.
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PURPOSE Papillary thyroid carcinoma (PTC) is frequently 
associated with diffuse lymphocytic thyoiditis (LT) at his-
tology and serum autoantibodies to thyroglobulin (TgAb) 
and to thyroperoxidase (TPOAb). The influence of LT and 
thyroid autoantibodies on the prognosis of PTC is debated. 
We evaluated the clinical course of a large group of PTC 
patients according to the presence or absence of LT (LT+ 
and LT-) and thyroid autoantibodies. METHODS We 
evaluated 194 consecutive and non-selected PTC patients 
treated with total thyroidectomy plus ¹³¹I ablation between 
2007 and 2009, followed for 7.2 years (mean). 72 patients 
had follicular variant of PTC, 97 classic, 16 tall cells and 
the remaining 9 others variants (solid or oxyphilic cells). LT 
was diagnosed in presence of >10 lymphocytes/field (40x). 
At the time of ablation, all patients underwent measure-
ment of Tg, TgAb and TPOAb, neck ultrasound and whole 
body scan. After ablation, patients underwent Tg (Beckman 
Coulter), TgAb and TPOAb (Tosoh) measurement and neck 
ultrasound (associated with other imaging if required) 
every 6-12  months. PTC was considered in remission ac-
cording to the following criteria: un-stimulated Tg <0.2 ng/
mL or stimulated Tg <1 ng/mL with TgAb <8 IU/mL and 
no evidence of structural disease. PTC was considered 
as persistent when un-stimulated Tg was ≥0.2  ng/mL or 
stimulated Tg was ≥1 ng/mL, or when TgAb were ≥8 IU/mL, 
or there was evidence of structural disease. RESULTS LT 
was found in 47% of patients, with a F/M ratio of 6.6/1, and 
was associated with a hypoechoic pattern at thyroid ultra-
sound (p = 0.05). At the end of follow-up 44/194 (22.7%) had 
persistent disease. Among them, 17/72 (23.6%) were follic-
ular, 19/97 (19.6%) classic, 6/16 (37.5%) tall cells and 2/9 
(22.2%) other variants. The time to remission was longer in 
the LT+ compared to the LT- patients (19.5 vs 7.5 months) 
(median) (p <0.001), in TgAb positive compared to TgAb 
negative patients (28.5 vs 7.5  months) (p <0.001) and in 
TPOAb positive compared to TPOAb negative patients 
(28.0 vs 8.0 months) (p = 0.005). At multivariate analysis 
TgAb were the only independent factor influencing the time 
to remission (0.54; 0.35-0.83; HR and confidence interval) 
(p = 0.001). However, evaluating only the 111 TgAb negative 
patients, the time to remission (undetectable un-stimulated 
or stimulated Tg and no evidence of structural disease) was 
similar in the LT+ and LT- groups (8.0 months for both). At 
variance, in 83 TgAb positive patients the time to remission 
was longer in LT+ than in LT- patients (29.3 vs 13.0 months) 
(p=0.01). CONCLUSIONS The time to remission is longer 
in LT+ compared to LT- PTC patients treated with total 
thyroidectomy plus ¹³¹I ablation. This is due to the frequent 
association of LT with TgAb, because undetectable TgAb is 
required to define the remission of PTC. Indeed, coexistent 
LT does not influence the time to remission when the anal-
ysis is restricted to TgAb negative patients.
Thyroid
THYROID NEOPLASIA AND CANCER
Polygenic Susceptibility to Papillary Thyroid Cancer 
in Italian Subjects
Giulia Brigante, PhD, MD1, Clara Lazzaretti, MSC1,  
Elia Paradiso, MSC1, Asta Foersti, MD, PhD2, Kari Hemminki, 
MD, PhD2, Rossella Elisei, Professor3, Cristina Romei, PHD3, 
Vincenzo Rochira, MD,PhD1, Manuela Simoni, MD,PHD1,  
Stefano Landi, PhD4, Livio Casarini, PhD5.
1Department of Biomedical, Metabolic and Neural Sciences, 
University of Modena and Reggio Emilia, Modena, Italy, 2Division 
of Molecular Genetic Epidemiology C050, German Cancer 
Research Center (DKFZ), Heidelberg, Germany, 3Department 
of Endocrinology, University Hospital, Pisa, Italy, 4Department 
of Biology, University of Pisa, Pisa, Italy, 51.Department of 
Biomedical, Metabolic and Neural Sciences, University of Modena 
and Reggio Emilia, Modena, Italy.
MON-486
Polygenic Susceptibility to Papillary Thyroid Cancer in 
Italian Subjects
INTRODUCTION AND AIM. Thyroid cancer is the most 
common endocrine neoplasia, with an estimated age-
standardized incidence rate of 6.7 per 100000 worldwide in 
2018 [1]. This rate is rapidly increasing and papillary thy-
roid carcinoma (PTC) is the main histotype. PTC suscepti-
bility is the result of genetic predisposition, environmental 
factors and lifestyle. We studied the genetic combination 
that characterizes PTC affected subjects, differentiating 
them from healthy controls.
METHODS AND RESULTS. We considered the genetic 
variants (SNPs) significantly associated with PTC on the 
PubMed database. 184 informative SNPs were selected, 
considering linkage disequilibrium. Then, SNPs data 
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comprising genome of 2504 unselected individuals col-
lected worldwide. The combination of 184 SNPs associ-
ated with PTC was used to group individuals in different 
risk-clusters according to their genetic structure, calcu-
lated by Bayesian statistics, as previously performed for 
polycystic ovary syndrome [2]. Individuals were distrib-
uted among 7 groups worldwide, indicating different de-
gree of genetic predisposition to PTC. We then considered 
genetic data from about 1200 individuals (697 PTC versus 
497 healthy controls) of Central/South Italian origin reg-
istered in a GWAS, specific for PTC [3]. This first analysis 
was refined using the 33 SNPs reasonably most causa-
tive of genetic clustering (26 with p<0.05 at trend test in 
GWAS and 7 with p<0.05 in the model of recessive inher-
itance). At multivariate logistic regression analysis, PTC 
and healthy controls resulted genetically different (ODDS 
RATIO 188.6, 95%CI 64.35-552.8), revealing diverse pre-
disposition to develop cancer. Afterwards, these results 
have been confirmed in an independent cohort of Italian 
subjects (234 PTC and 100 controls). Then, the genetic 
structure of each subject was indicated as a percentage of 
affinity to each risk-cluster and re-analyzed together with 
other risk factors: sex, body-mass index, area of origin and 
familiarity (quantified in a growing score as the degree of 
kinship increases). These data were analyzed together by 
principal component analysis and clustering of the two 
groups was even more pronounced. The most contributive 
factors to the diversity between PTC and healthy controls 
were genetics and familiarity.
CONCLUSION. We demonstrated that PTC affected 
subjects are genetically different from healthy controls, 
and that the difference is identifiable in a peculiar combi-
nation of genetic variants.
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Up to 5% of all pituitary tumors are hereditary (e.g. due 
to menin or AIP genes germline mutations). AIP gene 
mutations are more common in subjects with acromegaly, 
less than 30 years old at the onset of disease, and with FIPA 
family history.
The study was aimed at the assessment of the frequency 
and characteristics of AIP-mutation related tumors in non-
selected patients with pituitary macroadenomas.
Material and methods. The study included subsequent 131 
patients (57 males, 74 females; median age 42 years (IQR 
25  years) diagnosed with pituitary macroadenomas, and 
with a negative family history of FIPA or MEN1 syndromes. 
The following tumors were identified: 11 ACTH-secreting, 
49 GH-secreting (including 7 pluri-hormonal ones), 6 
gonadotropinomas, 23 prolactinomas, 1 TSH-oma, and 
43 non-secreting adenomas. Sanger sequencing was used 
for the assessment of AIP gene variants. The study was 
approved by the Ethics Board of JUMC.
Results. An AIP mutation was identified in five of 131 in-
cluded subjects (3.8%): one diagnosed with Cushing’s di-
sease, two with acromegaly, and two with non-secreting 
adenomas. In two patients, the identified mutation usually 
predisposes to ACTH-secreting adenomas, in two patients 
- mutations of unknown clinical significance were found 
(usually connected with pituitary adenomas), and the mu-
tation detected in one patient was described as benign. 
Patients harboring hereditary AIP gene variations did not 
differ from the rest of the study group in median age at 
diagnosis (41 vs. 42.5 years, p=0.8), median largest tumor 
diameter (25 vs. 24 mm, p=0.6), gender distribution (60% 
of females vs. 56.3%, p=0.8), secreting tumor frequency 
(60% vs. 67.5%, p=0.7), or acromegaly diagnosis frequency 
(40% vs.37.3%, p=0.9). 2 of the 5 patients with identified 
AIP gene mutations agreed for their families to be offered 
AIP genetic testing: (1) An AIP mutation was found in the 
asymptomatic mother of one acromegalic female patient. 
(2) The AIP mutation of unknown clinical significance was 
detected in the son of a male acromegalic patient with acro-
megaly, clinically unscreened yet.
Conclusions. In our series of apparently sporadic pituitary 
macroadenomas, AIP gene mutation carriers did not differ 
substantially from patients with negative genetic testing. 
A  risk factor-centered approach to AIP genetic screening 
may result in missing germline mutations, therefore, there 
is a need to establish if such a situation negatively impacts 
a patient’s and his/her family outcomes.
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Objective: To determine the frequency and associated 
factors with multidrug-resistant organism (MDRO) infec-
tion among patients with diabetic foot ulcers in a Peruvian 
Public Hospital.
Materials and methods. Cross-sectional survey was 
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